5 March 2018
Horizon Discovery hosts Capital Markets Day today
Cambridge, UK, 5 March 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon” or "the Group"), a global leader in gene editing and gene modulation technologies, will today hold a Capital Markets Day in London for institutional investors and analysts between 13:00 – 15:00 GMT / 08:00 – 10:00 EDT at Etc. Venues Fenchurch Street, 43/44 Crutched Friars, London, EC3N 2HH. Registration for those attending in person will begin at 12:30 to ensure a prompt 13:00 start. A light lunch will be provided. No new price sensitive information will be disclosed.
The agenda for the session, commencing at 13:00 GMT / 08:00 EDT today, will include:
- Richard Vellacott, Interim Chief Executive Officer: Horizon Strategy and Vision
- Richard Vellacott: FY17 Trading
- Terry Pizzie, Head of Commercial: Commercial Delivery
- Chris Lowe, Head of Research Operations: Delivery of our Research Operations
- Kim Nichols, Head of Global Operations: Dharmacon Business and Integration
- Jon Moore, Head of Translational R&D: Leveraged Research
- Tom Henley, Head of Innovation: Driving our Core Innovation
- Richard Vellacott: Summary and Q&A
The event will simultaneously be available via a live conference call and webcast at https://www.horizondiscovery.com/about-us/investor-relations. A recording will be made available shortly after the event.
To dial in to the conference call, please follow these numbers:
Dialling in from the UK: +44 (0)330 336 9411
Dialling in from the US: +1 929-477-0353
Confirmation code: 7131835
Please contact firstname.lastname@example.org if you would like to attend today’s event and have not already registered.
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Richard Vellacott, Interim Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon’s platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company’s own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.